Supplementary MaterialsAdditional document 1. CD8 expression. 12967_2019_2194_MOESM1_ESM.tif (50M) GUID:?3CEFDFBA-4BA5-4F13-AA74-8C0244DD7CE4 Additional file 2. Frequency of Treg cells in patients with CML receiving imatinib or 2nd generation TKIs. Panels (A) and (B) summarize the frequency of CD4+ Treg cells in patients with CML receiving imatinib (n?=?26) or 2nd generation TKIs (n?=?1 nilotinib, n?=?2 dasatinib, n?=?3 bosutinib and n?=?1 ponatinib). Panels (C) and (D) depict the frequency of CD8+ Treg cells in the same treatment categories. In the combination treatment group, 6 CML patients were treated with imatinib and 2 CML patients received nilotinib. 12967_2019_2194_MOESM2_ESM.tif Istradefylline (KW-6002) (32M) GUID:?4618E2D9-0372-43B6-BE73-90632B96D146 Additional file 3. Programmed death receptor 1 (PD-1) expression in patients with CML receiving imatinib or 2nd generation TKIs. Panels (A) and Istradefylline (KW-6002) (B) summarize the frequency of PD-1-expressing CD4+ T cells in patients with CML receiving imatinib (n?=?26) or 2nd generation TKIs (n?=?1 nilotinib, n?=?2 dasatinib, n?=?3 bosutinib and n?=?1 ponatinib). Panels (C) and (D) depict the frequency of PD-1-expressing CD8+ T cells in the same treatment categories. In the combination treatment group, 6 CML patients were treated with imatinib and 2 CML patients received nilotinib. 12967_2019_2194_MOESM3_ESM.tif (33M) GUID:?D6FAA7F3-F288-4F03-8D09-DF5C48505F3A Additional file 4. Frequency of myeloid-derived suppressor cells (MDSCs) in patients with CML receiving imatinib or 2nd generation TKIs. Panels (A-C) and (B-D) summarize the frequency of Gr-MDSCs and Mo-MDSCs, respectively, in patients with CML receiving imatinib (n?=?26) or 2nd generation TKIs (n?=?1 nilotinib, n?=?2 dasatinib, n?=?3 bosutinib and n?=?1 ponatinib). In the combination Istradefylline (KW-6002) treatment group, 6 CML patients were treated with imatinib and 2 CML patients received nilotinib. 12967_2019_2194_MOESM4_ESM.tif (31M) GUID:?EBB76CDE-87FA-44E9-A402-419366A4A148 Additional file 5. List of differentially expressed immune genes when comparing CML patients treated with TKIs plus IFN- and patients receiving TKIs alone. The differentially expressed genes (fold change?>?4 or?2) are ranked by corrected value. Data were analyzed using the nSolver? software package, version 4.0 (NanoString Technologies Inc., Seattle, WA). 12967_2019_2194_MOESM5_ESM.docx (16K) GUID:?4A4253D0-17CB-42EA-AF94-E2E5F0D158C3 Data Availability StatementThe datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request and for legitimate scientific use. Abstract Background Tumor cells have evolved complex strategies to escape immune surveillance, a process which involves NK cells and T lymphocytes, and various immunological factors. Indeed, tumor cells recruit immunosuppressive cells [including regulatory T-cells (Treg), myeloid-derived suppressor cells (MDSC)] and express factors such as PD-L1. Molecularly targeted therapies, such as imatinib, have off-target effects that may influence immune function. Imatinib has been shown to modulate multiple cell types involved in anti-cancer immune surveillance, with potentially detrimental or favorable outcomes. Imatinib and other tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) have dramatically changed disease course. Our study aimed to characterize the different populations of the immune system in patients with CML affected by their treatment. Methods Forty-one patients with CML [33 treated with TKIs and 8 with TKIs plus interferon (IFN)-] and 20 controls were enrolled in the present study. Peripheral bloodstream populations from the disease fighting capability [known to as the summary of disease fighting capability (OVIS) -panel, Treg?cells and MDSCs] and PD-1 appearance were evaluated?by movement cytometry. The immunological profile was evaluated using the mRNA Pan-Cancer Defense Profiling -panel and a NanoString nCounter FLEX system. Results Patients getting mixture therapy (TKIs?+?IFN-) had lower amounts of lymphocytes, particularly T cells [838/L (95% CI 594C1182)] weighed against healthy handles [1500/L (95% CI 1207 C 1865), p?=?0.017]. These sufferers also had an increased percentage of Treg (9.1%) and Compact disc4+PD-1+ cells (1.65%) weighed against handles [Treg (6.1%) and Compact disc4+/PD-1+(0.8%); p??0.05]. Furthermore, sufferers treated with TKIs acquired even more Mo-MDSCs (12.7%) whereas those treated with TKIs?+?IFN- had more Gr-MDSC (21.3%) in comparison to handles [Mo-MDSC (11.4%) and Gr-MDSC (8.48%); p??0.05]. Compact disc56bcorrect NK cells, a cell subset Istradefylline (KW-6002) endowed with immune-regulatory properties, had been increased in sufferers receiving IFN- plus TKIs weighed against those treated with TKIs alone. Interestingly, serum IL-21 was low in the TKIs as well as IFN- cohort significantly. Inside the SERPINA3 mixed band of sufferers treated with TKI monotherapy, we.
Categories